ENDRA Life Sciences Inc. current report, 10 October 2018

Full document

ENDRA Life Sciences Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on October 16, 2018, covering events occurring between October 10, 2018, and October 15, 2018. The Company is an emerging growth company incorporated in Delaware.

Key Financial Metrics

The filing details a completed underwritten public offering of common stock. Key financial figures include:

  • Shares Issued: 1,477,750 shares of common stock, plus an additional 192,750 shares pursuant to the full exercise of the underwriter's over-allotment option.
  • Total Shares Sold: 1,670,500 shares.
  • Net Proceeds: Approximately $2.7 million after deducting underwriting discounts, commissions, and other offering expenses.
  • Revenue, Profit, and Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.

Material Changes

The primary material change reported is the entry into a Material Definitive Agreement (Underwriting Agreement) with National Securities Corporation on October 11, 2018. The offering closed on October 15, 2018, resulting in a significant increase in the Company's cash liquidity through the net proceeds of $2.7 million.

Outlook, Risks, and Management Commentary

Management issued press releases on October 10, 11, and 15, 2018, regarding the offering, which are incorporated by reference. The offering was conducted pursuant to an effective registration statement on Form S-3. The filing does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the standard terms of the underwriting agreement.

Investor Verification Checklist

  • Verify the final closing price per share to calculate the gross proceeds before expenses.
  • Review the Underwriting Agreement (Exhibit 1.1) for lock-up periods or specific use of proceeds restrictions.
  • Confirm the impact of the new share issuance on existing shareholder dilution.
  • Check subsequent filings for the actual deployment of the $2.7 million in net proceeds.